Aldevron Breakthrough Blog
Presentation: CRISPR Genome Editing
December 31, 2024 by Aldevron
Solutions from Discovery to Clinic
Analytics. As the complexities of genome editing therapies grow, along with regulatory oversight, the need to analyze and characterize the quality of drug substances and drug products becomes a critical part of the development process.
In a presentation at the CRISPR-Based Therapy Analytical Development Summit, Coby Slagter-Jager, Aldevron’s Director of Analytical Development, touched on the analytics tools now available, and what might be expected in the future for analytics.
In her discussion of the analytical process, based on Aldevron operations, Slagter-Jager touched on proper use of phase-appropriate quality systems, client clinical case studies, QC testing, activity assays, and dealing with Cas9 quantification.
Watch CRISPR Genome Editing Solutions from Discovery to Clinic
- Have questions on this topic? Contact Coby Slagter-Jager
- Learn more about our CRISPR services
- Have an idea for a topic? Let us know!
Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in cGMP manufacturing and is known for inventing the GMP-Source® quality system. Aldevron operates the largest cGMP plasmid DNA manufacturing facility in the world at company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin.